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Abstract 
Background: The 52‑week monotherapy with the dipeptidyl peptidase‑4 inhibitor sitagliptin and the sulphonylurea 
glimepiride on early‑phase insulin secretion in Japanese patients with type 2 diabetes mellitus (T2DM) is not known.
Methods: A randomized, parallel‑group, open‑label trial was conducted at 18 centers between February, 2011 
and March, 2013. 171 outpatients with T2DM were recruited and randomly assigned to glimepiride or sitagliptin by 
minimization. Doses of glimepiride (0.25–1.0 mg/day) and sitagliptin (25–100 mg/day) were adjusted for hemoglobin 
A1c (HbA1c) > 6.9 %. Analyses were performed on full analysis set (FAS) of randomized subjects taking medications as 
allocated, and underwent 75 g oral glucose tolerance test (OGTTs) before and after treatment. The primary outcome 
was insulinogenic index to quantify early‑phase insulin secretion after treatment, which was evaluated by analysis of 
covariance (ANCOVA).
Results: Of 171 enrolled subjects, 68 in the sitagliptin group and 65 in the glimepiride group were included in the 
FAS (mean age, 64 years; baseline (HbA1c), 7.4 %). The primary outcome revealed a significantly higher insulinogenic 
index in the sitagliptin group than that in the glimepiride group (p = 0.036). Sitagliptin also reduced plasma glucose 
levels at 60 and 120 min during OGTT compared with glimepiride, while achieving a similar improvement in HbA1c 
during treatment. Body weight did not change in either of the two groups, and one case of hypoglycemia was 
observed in the glimepiride group.
Conclusions: Sitagliptin shows better effects on insulinogenic index after 52‑week treatment compared with glime‑
piride in Japanese patients with T2DM.
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Background
The high prevalence of type 2 diabetes mellitus 
(T2DM) is a worldwide public health concern. Asian 
countries are currently facing a greater burden of 
T2DM; more than 60 % of the world’s T2DM patients 
are in Asia [1].
Efficacy evaluation of treatment with diabetes com-
monly uses hemoglobin A1c (HbA1c); however, the level 
of this index does not allow for evaluation of treatment 
effects on insulin secretion or insulin resistance [2–4]. 
β-cell function in patients with T2DM is approximately 
50 % that of healthy individuals at the time of diagnosis, 
and decreases yearly thereafter [5]. Hence, evaluation of 
β-cell function as well as HbA1c is desirable for assess-
ment of drug efficacy in treatment of diabetes. An impor-
tant characteristic of T2DM is elevation of the fasting 
glucose level as well as that of postprandial glucose level, 
which are mainly affected by postprandial insulin secre-
tion. Insulinogenic index is commonly used to assess 
early-phase insulin secretion in response to glucose 
[6–8]. It is reported that a reduced insulinogenic index 
represents the main abnormality in the transition from 
normal glucose tolerance (NGT) to T2DM, resulting in 
the elevation of postprandial glucose levels in Asian sub-
jects [7–12]. In addition, maintenance of an appropriate 
insulinogenic index decreases incidence of microalbumi-
nuria in T2DM [13]. Considered together, these findings 
suggest that the insulinogenic index may be a critical fac-
tor in progression to T2DM, maintenance of postpran-
dial glucose levels, and prevention of the complications 
of diabetes.
The American Diabetes Association and European 
Association for the Study of Diabetes consensus for treat-
ing T2DM recommend biguanides as first-line therapy 
[14]. This treatment, however, has not been established 
in Asian countries, including Japan [15, 16]. Unlike the 
insulin resistance seen in Caucasians, Asian patients 
with T2DM have a relatively low BMI and a predominant 
insulin secretory defect [3, 7–12, 17–23]. Therefore, insu-
lin secretagogues, particularly sulfonylureas and dipep-
tidyl peptidase-4 (DPP-4) inhibitors are widely used in 
Japan [24]. Meta-analysis has shown that DPP-4 inhibi-
tors are more effective in Asian compared to non-Asian 
patients [23]. Effectiveness of DPP-4 inhibitors on insulin 
secretion stimulated by glucose for 12-week has shown 
in Korean patients with T2DM [25]. However, little is 
known the effects of DPP-4 inhibitors on the insulino-
genic index as the primary endpoint compared to sulfo-
nylureas monotherapy.
We conducted a multicenter, randomized controlled 
trial to compare the effect of glimepiride and sitagliptin 
on the insulinogenic index after 52-week treatment in 
Japanese patients with T2DM.
Subjects and methods
Trial design and participants
A randomized, open-label, parallel-group trial was con-
ducted over a period of 52 weeks from February 10, 2011 
to March 31, 2013 at 18 centers across Japan, including 
clinics and general and university hospitals. Eligibil-
ity criteria were outpatients with T2DM aged < 80 years 
with an HbA1c level < 8.4 % who had received no phar-
macological treatment for diabetes for at least 1  month 
prior to participation in this trial. Exclusion criteria were 
renal or liver dysfunction, pancreatic or hematological 
operation, severe complications of diabetes, being preg-
nant or possibly pregnant, malignancy under treatment 
and medications known to affect glucose metabolism.
Ethics
The protocol was approved by the University hospital 
Medical Information Network (UMIN) (Clinical Trial 
Registry No. 000004791), the Ethics Committee of Kyoto 
University Graduate School and Faculty of Medicine, as 
well as the Ethics Committee of each study center. The 
trial was performed in accordance with the Declaration 
of Helsinki upon obtaining written informed consent 
from all participants, and was reported in accordance 
with the Consolidated Standards of Reporting Trials 
(CONSORT) Statement [26].
Intervention and maintenance
Each participant was administered glimepiride (titrated 
upward to 1.0  mg) or sitagliptin (titrated upward to 
100  mg) once daily in the morning for 52  weeks. The 
starting dose was decided by the respective physicians 
based on the baseline condition of each participant. 
When HbA1c levels exceeded 6.9  % after 6  months or 
later, glimepiride and sitagliptin doses were increased to 
each titrated dose. Physicians were allowed to decrease 
the doses at any point to prevent the occurrence of a 
hypoglycemic event. On the other hand, if participants 
did not meet the specified glycemic control criteria with 
the setup dose, physicians were allowed to add or switch 
medications and the participants were discontinued from 
the trial.
Outcome measurements
The primary outcome measurement was the difference 
in post-treatment insulinogenic index between the two 
groups. Secondary outcome measurements were the 
levels of plasma glucose (PG) (mmol/l), immunoreactive 
insulin (IRI) (pmol/l), C-peptide (CPR) (nmol/l), gluca-
gon (ng/l) (Millipore Corporation, Bilerica, MA), and 
insulin sensitivity index (ISI; an index of insulin resist-
ance) during 75  g oral glucose tolerance tests (OGTTs) 
before and after 52-week treatment [27]. In addition, 
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HbA1c (%), glycated albumin (GA) (%), and BMI (kg/
m2) after treatment also were evaluated as secondary 
outcome measurements. Each outcome was calculated 
as follows: HbA1c was expressed as a National Glyco-
hemoglobin Standardization Program (NGSP) equiva-
lent value calculated by the following formula: HbA1c 
(NGSP value) (%) = 1.02 × HbA1c (Japan Diabetes Soci-
ety value) (%) + 0.25 [28]. The estimated glomerular fil-
tration rate (eGFR) (ml/min/1.73  m2) was calculated by 
194 ×  serum Cr−1.094 × age−0.287 for men, 194 ×  serum 
Cr−1.094 × age−0.287 × 0.739 for women [29]. The insuli-
nogenic index was calculated by the following equation: 
(IRI at 30 min - fasting IRI)/(PG at 30 min—fasting PG) 
[6–8]. ISI composite was calculated by 10,000/{[fasting 
PG (mmol/l) × fasting IRI (pmol/l) × mean 75 g OGTT 
PG (mmol/l)  ×  mean 75  g OGTT IRI (pmol/l)]0.5}1/3 
[27].
Sample size
Given the lack of differences and variance in the insuli-
nogenic index between two similar groups in a previ-
ous study, an effect size of 0.6, which is conventionally 
accepted as a medium effect, was used to calculate an 
appropriate sample size. We estimated that 100 partici-
pants would provide at least 80 % power to detect a sta-
tistically significant difference (α = 0.05, two-sided test, 
and withdrawal rate of 10  % per year) between the two 
groups.
Randomization
We used the UMIN system, a computer-generated ran-
dom sequence, to assign participants to either glime-
piride or sitagliptin in a 1:1 ratio by minimization, based 
on sex, center, age, and HbA1c. Collaborating physi-
cians enrolled the participants, and during the follow-up 
period, this trial was performed without blinding. That 
is, both physicians and participants were aware of which 
drug was allocated.
Procedures
Upon obtaining informed consent, OGTTs were per-
formed before (0 week) and after 52-week treatment. The 
levels of PG, IRI, CPR, and glucagon were measured at 
0, 15, 30, 60, and 120  min (min) during OGTTs. After 
treatment, OGTTs were performed with a 24-h wash-
out period. GA was measured at 0 and 52  weeks, and 
glutamic acid decarboxylase (GAD) antibody was meas-
ured at 0  week. HbA1c, PG, body weight, and clinical 
biochemical tests were measured (0, 4, 12, 24, 36, and 
52 weeks). Safety monitoring for hypoglycemia was per-
formed during treatment. All samples were labeled with a 
code assigned to each participant and routinely analyzed 
at a laboratory of the SRL Corporation (Tokyo, Japan).
Statistical analyses
All statistical analyses were performed with a blind pro-
cedure by an independent third party, Statcom Com-
pany Limited. For the primary outcome measurement, 
the main analysis was performed on the full analysis set 
(FAS) of all randomized participants who took medi-
cations as allocated and underwent the OGTTs before 
and after treatment, excluding those with a hemolyzed 
sample, those who were added or changed therapy, and 
those who were withdrawn from the trial before treat-
ment following consent acquisition. Subgroup analysis 
was performed on the per-protocol set (PPS), which 
excluded positive result of GAD antibody, protocol 
violations, or poor compliance from the FAS. Analy-
sis of covariance (ANCOVA) was used to evaluate the 
primary outcome measurement based on baseline log-
transformed insulinogenic index, and allocation vari-
ables, including age, sex, and HbA1c as covariates. For 
secondary outcome measurements, repeated meas-
ures analysis using a mixed model with terms for visit, 
treatment, and interaction was performed for OGTT, 
HbA1c, and BMI, including baseline values as covari-
ates. Least-squares means (lsmeans) with 95  % confi-
dence intervals (CIs) were obtained from the model, 
estimating from the mixed model. Other secondary 
outcome measurements were compared between the 
two groups using Analysis of variance (ANOVA) for 
the evaluation of GA and ISI. As an exploratory analy-
sis, the change of insulinogenic index in each group 
was analyzed by Paired t test. The achievement rate of 
HbA1c < 7.0 % between the two groups were compared 
by Fisher’s Exact test. All statistical analyses were per-
formed using SAS version 9.2 (SAS Institute Inc, Cary, 
NC) and JMP® 9 (SAS Institute Inc., Cary, NC, USA). 
No interim analysis was performed.
Results
Flow chart of participants
A total of 196 participants were recruited for this trial 
(Fig. 1). Of these, 25 participants who did not meet the 
inclusion criteria were excluded. The remaining 171 par-
ticipants were randomly assigned to sitagliptin or glime-
piride groups in a 1:1 ratio. Of these, 133 participants 
(glimepiride, n =  68; sitagliptin, n =  65) were analyzed 
as the FAS, with a final follow-up rate of 77.8 %. In the 
glimepiride group, 62 participants were regarded as 
the PPS, which excluded six participants due to posi-
tive results of GAD antibody (n = 3), protocol violations 
(n  =  2), or poor compliance (n  =  1). In the sitagliptin 
group, the number of participants in the FAS and PPS 
was the same. The main reason for discontinuation in 
both groups was due to hemolysis of samples. Other rea-
sons included dropout from treatment, addition of other 
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drugs due to hyperglycemia, or insulin therapy under 
hospitalization.
Demographics and participant characteristics in the FAS
All variables were well balanced between the two groups 
in FAS, and also divided into the same balance in the 
baseline (Table  1). Participants were middle-aged, had 
a mean BMI of 24.4 (3.6) (kg/m2), had short duration of 
diabetes, and had no severe renal dysfunction. They had 
started treatment with oral hypoglycemic agents at an 
HbA1c of 7.4 (0.5) %. Participant characteristics (i.e., low 
BMI, low insulin secretion, and low insulin resistance) 
are comparable to those of Asian T2DM patients previ-
ously reported [3, 7–12, 17, 18, 22–25]. The usual starting 
dose of glimepiride was 0.5 mg/day; that of sitagliptin was 
50  mg/day. Eighteen patients had taken diabetic medi-
cation before enrollment as follows; biguanide (n  =  1), 
insulin (n = 1), glinides (n = 4), alpha glucosidase inhibi-
tors (n = 4), and sulfonylureas (n = 8). They had not used 
these antidiabetic treatments for at least 3 months before 
enrollment. Especially, eight patients who took sulfonylu-
reas were divided into the two groups equally.
Primary outcome measurement
Insulinogenic index after 52-week treatment was sig-
nificantly higher in the sitagliptin group than in the 
glimepiride group (p  =  0.036) in the FAS (Fig.  2a). No 
interactions between the drugs and other adjusted factors 
were observed. Associations between insulinogenic indi-
ces and PG levels at 60, and 120 min during OGTT were 
evaluated. Insulinogenic indices were more negatively 
correlated with PG levels at 60 min than those at 120 min 
(R2 = 16 %, data not shown). The obtained linear regres-
sion equation in total is as follows: log post-treatment 
insulinogenic indices (pmol/mmol)  =  4.8  −  0.1  ×  PG 
levels at 60  min (mmol/l) (R2, coefficient of determina-
tion = 35 %, p < 0.0001 in total, 38 %, 30 % in sitagliptin 
and in glimepiride, respectively) (Fig. 1b).
Secondary outcome measurements
The levels of PG, IRI, CPR, and glucagon during OGTTs 
were compared after both treatments (Fig. 3). PG levels 
at 60 min (p < 0.01) and 120 min (p < 0.001), and over-
all (p  <  0.001) were significantly lower in the sitagliptin 
group than those in the glimepiride group (Fig. 3a). The 
Eligibility
N=196 
Per protocol set    
N=62 
Per protocol set   
   N=65 
Full analysis set   
  N=68 
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N=21  withdrawn 
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N=1 abdominal pain 
N=1 job transfer  
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N=1 pancreac cancer  
Fig. 1 Flow chart of participation
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levels of IRI, CPR, and glucagon did not differ between 
the two groups (Fig. 3b–d). We also compared the levels 
of PG, IRI, CPR, and glucagon during OGTTs between 
pre-treatment and post-treatment in each group (Addi-
tional file  1: Figure S1A–H). PG levels at 30, 60, and 
120  min in glimepiride group were significantly lower 
after treatment than those before treatment (Additional 
file  1: Figure S1A), while PG levels at 60 and 120  min 
in sitagliptin group were significantly lower after treat-
ment than those before treatment (Additional file 1: Fig-
ure S1B). In both groups, the level of overall glucose was 
significantly lower than that before treatment. The over-
all insulin level was significantly higher after treatment 
only in sitagliptin group (p  <  0.05) (Additional file  1: 
Figure S1C, D). The level of overall CPR was increased 
after treatment in both groups compared to that before 
treatment (Additional file  1: Figure S1E, F) (p  =  0.001, 
p < 0.001, respectively). All points of insulin and C-pep-
tide levels during OGTT did not change between before 
and after 52  weeks treatment in each group. The level 
of glucagon, including overall level, was not signifi-
cantly changed between before and after treatment in 
each group (Additional file  1: Figure S1G, H). Insulino-
genic index after treatment was significantly higher than 
that before treatment in each group (p < 0.05, p < 0.001, 
respectively) (Data not shown).
HbA1c improved gradually from 7.4  % to 6.8 (6.7–
7.0)  % at 12  weeks, and remained the same until 
52  weeks (Additional file  2: Figure S2). There was no 
significant difference in HbA1c levels between the two 
groups during 52-week treatment. Neither the post-
treatment levels of HbA1c nor GA showed significant 
difference in the two groups (Table 2) (p = 0.79, p = 0.3, 
respectively). The achievement rate of HbA1c  <  7.0  % 
also showed no significant difference between the two 
groups (61.8, 67.7  %, respectively, p =  0.586). ISI was 
significantly and slightly higher in sitagliptin group 
than that in glimepride group (p = 0.046). BMI did not 
differ after treatment (p  =  0.75) (Table  2) and during 
the follow-up period (data not shown) between the 
two groups. At 52-week, the final dose of glimepiride 
was 0.25  mg/day (13.2  %), 0.5  mg/day (72.1  %), and 
1.0 mg/day (14.7 %), and that of sitagliptin was 25 mg/
day (6.2 %), 50 mg/day (83.1 %), 75 mg/day (1.5 %), and 
100 mg/day (9.2 %).
The single, self-reported episode of mild hypoglycemia 
was experienced during exercise in the glimepiride group; 
no severe hypoglycemia was reported in either group. 
Table 1 Participant characteristics in the full analysis set
Data are expressed as means (SD), median with interquartile range (IQR), 
number (%), or percent (%)
Data were analyzed ANOVA or Fisher’s Exact test
No significant differences were observed between the two groups
BMI body mass index, HbA1c hemoglobin A1c, ISI insulin sensitivity index, GA 
glycated albumin, eGFR estimated glomerular filtration rate
Variables Glimepiride (n = 68) Sitagliptin (n = 65)
Male/female (number, %) 49/19 (72.1/27.9 %) 49/16 (75.4/24.6 %)
Age (year) 64 (8) 63 (9)
BMI (kg/m2) 24.7 (3.3) 24.1 (3.8)
Duration (year) 6.0 (5.1) 6.2 (6.0)
HbA1c (NGSP, %) 7.5 (0.5) 7.4 (0.5)
GA (%) 19.5 (2.8) 19.4 (2.7)
eGFR (ml/min/1.73 m2) 74.9 (14.0) 76.2 (17.1)




2.6 (2.1, 3.3) 2.2 (1.9, 2.8)
Starting dose (mg/day) 0.25 (20.6 %) 25 (12.3 %)
0.5 (77.9 %) 50 (87.7 %)
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Fig. 2 a Box and dot plots of log‑transformed post‑treatment 
insulinogenic index for glimepiride and sitagliptin groups. Analysis of 
covariance (ANCOVA) revealed a significantly higher post‑treatment 
insulinogenic index in the sitagliptin group (p = 0.036) in the FAS. 
b Scatter plot and linear regression equation in total: log post‑treat‑
ment insulinogenic index (pmol/mmol) = 4.8 − 0.1 × PG at 60 min 
(mmol/l) (R2, coefficient of determination = 35 %, p < 0.0001)
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One participant in the sitagliptin group had abdominal 
pain and discontinued treatment. Three participants in 
the sitagliptin group showed more than a 1.3-fold increase 
in creatinine relative to baseline. Hepatic-related side 
effects were considered when laboratory values exceeded 
threefold upper limit of the normal range. Alanine ami-
notransferase (ALT) was elevated in five participants 
(glimepiride group, n = 1; sitagliptin group, n = 4); how-
ever, all had baseline ALT exceeding the limit of normal 
range. Aspartate aminotransferase (AST) was elevated in 
one participant in the glimepiride group.
Discussion
In this trial, sitagliptin monotherapy resulted in signifi-
cantly higher insulinogenic index compared with that 
of glimepiride monotherapy in Japanese patients with 
T2DM after 52-week treatment (Fig.  2a). It is reported 
that the DPP-4. Inhibitors conserved β-cell function in 
patients with T2DM and autoimmune diabetes [30, 31]. 
Our result is possibly due to conserving β-cell function by 
DPP-4 inhibitor. In addition, the insulinogenic index was 
negatively correlated with glucose levels at 60 min during 
OGTT after treatment (Fig. 2b). This result suggests that 
maintenance of the insulingenic index is important to 
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Fig. 3 The levels of PG (a), IRI (b), CPR (c), and glucagon (d) during OGTT after 52‑week treatment. Filled circles with a dotted line: post‑glimepiride 
treatment; filled circles with a solid line: post‑sitagliptin treatment. Values show least‑squares mean with 95 % confidence interval (CI) estimated by 
a mixed‑model for repeated measures analysis. a p < 0.001 glimepiride vs. sitagliptin, *p < 0.01, ** p < 0.001 vs. glimepiride at each time point. b–d 
not significant (n.s.) at each time point
Table 2 Post-treatment comparison of physical and chemi-
cal parameters in the full analysis set
Data are expressed as least-squares mean with 95 % confidence interval (CI) in 
BMI and HbA1c, means (SD) in GA, or median with interquartile range (IQR) in ISI
Analysis of variance (ANOVA) revealed a significant difference in the two groups
BMI body mass index, HbA1c hemoglobin A1c, GA glycated albumin, ISI insulin 
sensitivity index




Sitagliptin (n = 65) p value*
BMI (kg/m2) 24.5 (24.2, 24.7) 24.5 (24.3, 24.8) 0.75
HbA1c (NGSP  %) 6.8 (6.7, 7.0) 6.8 (6.7, 7.0) 0.79
GA (%) 17.4 (2.8) 17.7 (2.6) 0.30
ISI (l2/mmol pmol) 15.8 (9.4, 20.8) 17.3 (11.9, 23.5) 0.046*
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indicates that sitagliptin may have a better effect on low-
ering the postprandial plasma glucose levels than glime-
pride in Asian patients with T2DM. It was reported that 
DPP-4 inhibitors including sitagliptin suppress glucagon 
secretion [32, 33]. However, there were no effects of sit-
agliptin on glucagon secretion in this trial. This result 
suggests that the effect of sitagliptin on insulin secre-
tion but not on glucagon secretion might continue after 
a drug washout period of 24 h after 52-week treatment.
Insulin secretion stimulated by sulfonylureas is inde-
pendent of the glucose concentration, while DPP-4 inhibi-
tors increase an active form of incretin peptide by DPP-4 
inhibition and potentiate glucose-dependent insulin secre-
tion [34–36]. Accordingly, sulfonylureas are associated with 
risk of hypoglycemia and weight gain; DPP-4 inhibitors are 
associated with lower frequency of hypoglycemia and are 
weight neutral [34–36]. In this trial, there was no hypo-
glycemia or weight gain in the sitagliptin group (Tables 1 
and 2). However, it should be noted that glimepiride treat-
ment also did not induce weight gain or incidence of severe 
hypoglycemia (Tables 1 and 2). This might be attributed to 
the low-dose of glimepiride used. Based on the Japanese 
claims database, 72  % of patients with single sulfonylu-
rea treatment used 1.0 mg/day for 1 year, and 70 % of the 
patients treated with 1.0  mg/day of glimepiride achieved 
1.0 % reduction of HbA1c [37]. Thus, the dose of glimepir-
ide was set to 1.0 mg/day in this trial. Consequently, a simi-
lar reduction in HbA1c levels was observed during 52-week 
treatment and no significant differences were found in 
HbA1c and GA levels between the two groups (Table  2, 
Additional file 2: Figure S2). These results made it possible 
to evaluate insulin secretion under the same glucose con-
trol conditions. Accordingly, the dose selection of less than 
1.0  mg/day of glimepiride, the effect of which on HbA1c 
reduction is comparable to that of less than 100 mg/day of 
sitagliptin, seemed reasonable in this trial. In addition, our 
results also suggest that in regard to HbA1c-lowering effi-
cacy, a low-dose of glimepiride is similarly effective as sit-
agliptin without weight gain or severe hypoglycemia at the 
early stage of T2DM with low insulin secretion (Table 2 and 
Additional file 2: Figure S2). Although a similar reduction 
in HbA1c and GA was achieved, post-challenge plasma 
glucose levels were significantly lower with sitagliptin than 
with glimepiride (Table  2, Fig.  3a, and Additional file  2: 
Figure S2). This result indicates that sitagliptin has better 
effects on insulinogenic index after 24-h wash out period at 
52-week treatment.
This trial has several limitations. First, low-dose glime-
piride was used in Japanese patients with T2DM who 
have low BMI and insulin secretion [3, 7–9, 12, 17, 22–
25]. The maximum dose of glimepiride was set at 1.0 mg/
day to achieve the same improvement of HbA1c between 
the two groups. Although a significantly better level of 
insulinogenic index was shown by glimepiride treatment 
(p < 0.05, data not shown), it is unknown to what extent 
high-dose glimepiride improves the insulinogenic index 
or HbA1c in Japanese patients with T2DM. Second, 
meal tolerance tests (MTTs) were not performed in this 
trial. The primary endpoint is to evaluate early-phase 
insulin secretion in response to glucose. The insulino-
genic index has already been established as an index of 
early-phase insulin secretion during OGTT [6–8]. How-
ever, the indices of the meal-stimulated insulin secretion 
by MMTs have not established, mainly because the total 
calories and contents of the meal differ among the pre-
vious studies [32, 33]. Third, the follow up rate of 78 % 
might be relatively low. The main reason is hemolysis 
of samples, which are important for the calculation of 
insulinogenic index. If we had planned to use multiple 
imputation method for missing data in the protocol, we 
might obtain higher follow up rate. The strength of this 
trial lies in its design, i.e., a multicenter, randomized, 
controlled trial involving clinics and a university hospi-
tal, which enhances the generalizability of our results. 
Furthermore, an active-controlled trial comparing the 
most widely used insulin secretagogues is practical for 
a daily clinical setting. This trial focused on the patho-
physiology and treatment efficacy of T2DM in Asia. Our 
finding of a better effect on early-phase insulin secretion 
is of clinical importance for Asian patients with T2DM.
In conclusion, sitagliptin showed better effects on insu-
linogenic index after 52-week treatment compared to 
glimepiride in Japanese patients with T2DM. Further 
research is required to assess early-phase insulin secretion 
in patients treated with these drugs for longer period.
Additional files
Additional file 1: Figure S1. The levels of PG (A and B), IRI (B and D), CPR 
(E and F), and glucagon (G and H) during OGTT before and after 52‑week 
treatment in glimepiride (A, C, E, and G) and sitagliptin groups (B, D, F, and 
H). Outlined circles with a dotted line: pre‑glimepiride treatment, filled 
circles with a solid line: post‑glimepiride treatment. Outlined squares 
with a dotted line: pre‑sitagliptin treatment, filled squares with a solid 
line: post‑sitagliptin treatment. Values show least‑squares mean with 
95 % confidence interval (CI) estimated by a mixed‑model for repeated 
measures analysis. Asterisks indicate significant differences between pre‑
treatment and post‑treatment at each time point († p < 0.05, †† p < 0.01, 
††† p < 0.001). A) p < 0.001 pre‑ vs. post‑glimepiride. † p < 0.05 at 30 and 
60 min and †† p < 0.01 at 120 min pre‑ vs. post‑glimepiride. B) p < 0.001 
pre‑ vs. post‑sitagliptin. ††† p < 0.001 at 60 and 120 min pre‑ vs. post‑
sitagliptin, C) not significant (n.s.) at each time point, D) p < 0.05 pre‑ vs. 
post‑sitagliptin, E) p = 0.001 pre‑ vs. post‑glimepiride, F) p < 0.001 pre‑ vs. 
post‑sitagliptin, G) n.s. at each time point, H) n.s. at each time point.
Additional file 2: Figure S2. Time course of HbA1c from baseline to 
52 weeks in the FAS. White circles with a dotted line: glimepiride group, 
filled black circles with a solid line: sitagliptin group. Values show least‑
squares mean with 95 % confidence interval (CI) estimated by a mixed‑
model for repeated measures analysis, including terms for baseline HbA1c 
visit and treatment by visit interaction. There was no significant difference 
between the two groups at any point.
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